림프종

425개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved425 programs
CGTLimited DatastaleCoronado Biosciences, Inc.Phase 2

Allogeneic natural killer cells (Allogeneic natural killer cells)

Leukemia; Lymphoma · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 58Status Discontinued
AntibodyLimited DatastaleNovartisApproved

Basiliximab (Basiliximab)

Type 1 Diabetes Mellitus · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#Antibody#Approved#Popular#monoclonal-antibody+2
Trials 58Status Active
AntibodyStandard DatabasestaleSeagen Inc.Phase 2

anti-CD30 mAb (SGN-30, SGN-30 (anti-CD30 mAb))

Anaplastic Large-Cell Lymphoma · CD30

#CD30#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 58Status Active
ADCLimited DatastaleSeagenvedotin-containing regimen …Phase 2

BV (BrentuximabVedotin, BrentuximabVedotin (BV))

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 56Status Active
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTStandard DatabasestaleKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

DLBCL; Diffuse Large B Cell Lymphoma · FRα

#FR#CGT#Approved#Popular#cell-gene-therapy+5
Trials 53Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
AntibodyLimited DatastaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 52Status Recruiting
ADCStandard DatabasestaleRochevedotin, rituximab, cycloph…Phase 2

Polatuzumab (Polatuzumab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 52Status Recruiting
ADCLimited DatastaleSeagenvedotin-containing regimen …Preclinical

SGN-35 (brentuximab vedotin, brentuximab vedotin (SGN-35))

Hodgkin Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 52Status Active
AntibodyLimited DatastaleSeagenPhase 2

Brentuximab (Brentuximab)

Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Discontinued
ADCStandard DatabasestaleSeagenvedotin-containing regimen …Phase 2

Adcetris (Brentuximab vedotin, Brentuximab vedotin (Adcetris))

Anaplastic Large Cell Lymphoma, ALK-Positive · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 51Status Recruiting
AntibodyLimited DatastaleBiogenPhase 2

90-Y-ibritumomab tiuxetan (90-Y-ibritumomab tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Biogen
Trials 49Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD7 CAR T-cells (CD7 CAR T-cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma · Crohn Disease

#CrohnDisease#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 49Status Active
AntibodyLimited DatastaleMridula George, MDPhase 2

Retifanlimab (Retifanlimab)

Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+3
Trials 49Status Recruiting
ADCStandard DatabasestaleADC TherapeuticsPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+2
Trials 48Status Recruiting

2 / 22 pages

← PreviousNext →